Matrix Partners China, a joint venture fund between U.S. venture capital firm Matrix Partners and its Chinese partners, has led a RMB100 million (US$15.8 million) financing round in Chinese genetics testing and analyzing start-up 23Mofang.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
